Autopsy report · NCT03742349

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

“This was a sponsor decision and was not a consequence of any safety concern”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 4 years before it stopped.
• 64 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Triple Negative Breast Cancer (TNBC)

Interventions

spartalizumab; LAG525; NIR178; capmatinib; MCS110; canakinumab

Participants

64

Sites

13

Countries

Australia, Hong Kong, Israel, Italy, Japan, Netherlands, Singapore, Spain, United States

Trials that died the same way

• Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program
  “Sponsor decision not related to safety concerns” (89% match in meaning)
• Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
  “Sponsor decision; the decision is not related to any safety concern.” (89% match in meaning)
• REGENETEN™ Bioinductive Implant System in Full-thickness Tears
  “Sponsor decision not related to safety.” (88% match in meaning)
• Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
  “Sponsor decision not related to safety reasons” (87% match in meaning)
• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
  “Sponsor decision, not for safety reasons.” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.